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1. INTRODUCTION 
Fluorescently labelled LH-RH has been visualis- 
ed as initially binding uniformly to the surface of 
pituitary gonadotrophs, then to aggregate, and 
finally become internalised [1,2]. Internalised LH- 
RH is thought to be sequestered and degraded by 
lysosomes [2] but may also become associated with 
other subcellular organelles and serve a regulatory 
function [3]. LH-RH stimulates LH release in a 
biphasic manner [4-61; an initial rapid phase 
followed by a slower phase which is dependent on 
protein synthesis [4,6]. Since LH-RH stimulation 
of the anterior pituitary is known to increase the 
biosynthesis of gonadotrophic hormones [7] and 
the number of LH-RH receptors [8] it is possible 
that one of its sites of action is the nucleus. Inter- 
nalisation and nuclear binding of peptide hor- 
mones has been demonstrated for insulin [9-l 11, 
EGF [12], NGF [13,14], LH [IS] and thyrotropin 
releasing hormone [ 161. Therefore, we have ex- 
amined the binding of LH-RH and its analogues to 
purified anterior pituitary nuclei. 
2. MATERIALS AND METHODS 
2.1. Preparation of nuclei 
Rats were decapitated, the anterior pituitary 
gland dissected out and diced in Tris-HCl 10 mM, 
EDTA 1.5 mM, BSA O.l%, DTT 1 mM, pH 7.4 
(TEBD) at 4°C. After several washings with this 
buffer the tissue was homogenized in a Dounce 
homogenizer (15 strokes), taken up in 20 ml buffer 
and centrifuged at 1000 x g for 10 min to yield a 
crude nuclear pellet. The supernatant was cen- 
trifuged at 20000 x g for 20 min to give a crude 
membrane preparation [ 171. Purified nuclei were 
prepared by a method modified from [18,19]. The 
crude nuclear pellet was resuspended in a 2.3 M 
sucrose, 15 mM Tris-HCl, 25 mM KCl, 1.5 mM 
MgCl2 (pH 7.5) and centrifuged at 18000 x g for 
10 min. The pellet was resuspended in the same 
buffer and centrifuged at 30000 x g for 30 min. 
Phase contrast microscopy revealed a preparation 
of single unclumped nuclei and an apparent 
absence of contaminating subcellular material. 
This picture was confirmed by electron microscopy 
and the nuclei shown to be intact with both inner 
and outer nuclear membranes present. The total 
5 ’ -nucleotidase activity [20] in the nuclear 
preparation was 4% of that of the membrane frac- 
tion resulting from the same preparation. In some 
studies requiring processing of a large number of 
groups of pituitaries, purification of nuclei was 
achieved by centrifugation through 1.2 M sucrose 
(see table 3). 
2.2. Binding studies 
D-Trp6-des-Gly”-LH-RH-ethylamine (D- 
Trp6-agonist) and D-Ala6-N-Me-Leu’-des-Gly’O- 
LH-RH-ethylamide (D-Ala6-agonist) (gifts from J. 
Rivier) were radioiodinated with “‘1 by the 
chloramine T method [21,22] and purified by 
Whatman CM32 carboxymethyl cellulose 121) and 
QAE Sephadex A-25 chromatography [23], respec- 
tively. Specific activity as determined by self- 
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displacement from a specific antiserum [21] or 
from pituitary membranes varied from 990-1250 
,&i/pg. The proportion of ‘*?-LH-RH analogue 
bound by excess pituitary membranes was 
33-40070. Preparatiqns (containing 0.3-2.25 
pituitary equivalents) were incubated with 
70000 dpm 1251-LH-RH agonist, and unlabelled 
LH-RH, LH-RH analogues or other peptides in 
500 ~1 at 4°C for 90 min. Non-specific binding was 
determined by the addition of 10m6 M of the 
homologous LH-RH analogue. Incubation was 
terminated by the addition of 3 ml cold phosphate- 
buffered saline containing 1% BSA to the tubes 
and filtration through presoaked Whatman GF/C 
Peptide (M ) 
filters. Filters were washed 3 times with 3 ml 
PBS-BSA and counted in a gamma counter. All 
determinations were done in triplicate and the data 
presented as the mean. 
3. RESULTS 
Nuclear binding of LH-RH agonists comprised a 
single class of saturable, high affinity, specific sites 
similar to pituitary membrane receptors (fig. 1). 
Nuclear and membrane binding sites were similar 
in their interaction with the D-Ala6-agonist, LH- 
RH and biologically inactive peptides (fig. 1, table 
1). As a check on the validity of these estimations, 
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Fig. 1. An example of displacement curves of ‘25 I-D-Ala6-N-Me-Leu7-des-Gly10-LH-RH-ethylamide by D-Ala6-N- 
Me-Leu7-des-Gly10-LH-RH-ethylamide (o), an antagonist, D-pGlu1-D-PheZ-D-Trp3*6-LH-RH (H) and LH-RH (A) 
from a single study using male rat anterior pituitary membranes (left) and nuciei (right). Scatchard plots of the agonist 
(0) data are shown in the insets. Each point is the mean of 3 determinations using material derived from 2.25 pituitary 
equivalents. 
Table 1 
Apparent &-values of LH-RH and analogues 
Agonist 
D-Ala6-N-Me-Leu’ - 
Antagonist Native 
D-pGlu’-D-Phe2-D-Trp3*6 - LH-RH 
LH-RH-ethylamide LH-RH 
Membranes 0.30 * 0.03 (5) 0.32 + 0.06 (3) 9.7 + 3.2 (3) 
Nuclei 0.22 * 0.03 (7) 0.66 f 0.31 (4) 16.2 f 14.2 (3) 
Kd-values [nM; mean + SEM (number of determinations)] were determined by Scatchard analysis or as in [24], and 
are the mean of values obtained from separate binding curves which employed both male and female rats. Mean binding 
;f the D-Ala6-agonist to membranes and nuclei was 29.7 f 1.6 and 13.0 f 1.7 fmol/pituitary equivalent, respectively 
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the & of ‘2sI-D-A1a6-agonist was also estimated 
from the association (ken) and dissociation (k,fr) 
rate constants and found to be 3.4 x lo-” M and 
0.8 x lo-” M for the membrane and nuclear 
preparations, respectively. Although the &I of the 
LH-RH antagonist binding to nuclei was higher 
than that of the membranes (table l), the dif- 
ference was not significant and more extensive 
studies with LH-RH analogues are required to 
determine whether there are differences in the bin- 
ding sites. 
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pituitary membrane fraction (1000 x g superna- 
tant) prepared from the same weight of anterior 
pituitary tissue, rehomogenized, and subjected to 
the usual purification procedures. Purified liver 
nuclei did not bind “‘1-LH-RH analogue but ex- 
hibited low but distinct binding after homogeniza- 
tion with the pituitary membrane fraction (table 
2). When the nuclei were prepared in the presence 
of 0.001% Triton X-100 no binding was detectable 
in liver nuclei while pituitary nuclei retained 8 1% 
of the binding (table 2). 
The possibility of contamination of the purified During the rat estrous cycle both nuclear and 
nuclei with plasma membranes containing LH-RH membrane binding was lowest at estrus and 
receptors was checked by quantitating diestrus I and increased at diestrus II to reach 
5 ‘-nucleotidase activity. Specific binding of ‘*‘I- highest levels during the morning of proestrus 
LH-RH analogue relative to 5 ’ nucleotidase activi- (table 3). There was no significant change in the af- 
ty was 25-fold higher in the purified nuclear finity of nuclear or membrane binding sites for 
preparation. To further rule out the possibility that LH-RH during the estrous cycle. In these studies 
nuclear binding of LH-RH was due to contamina- nuclear binding was determined using nuclei 
tion with other subcellular material, we in- prepared by centrifugation through I .2 M sucrose. 
vestigated LH-RH binding by liver nuclei prepared Light microscopic examination of haematoxylin- 
along with pituitary membranes. Purified nuclei eosin-stained preparations indicated that the nuclei 
were prepared from rat liver, mixed with a were uncontaminated. However, since we have not 
Table 2 
Specific binding (cpm) of ‘251-D-Trp6-des-Gly10-LH-RH-ethylamide to pituitary and liver nuclei 
Triton Pituitary Liver nuclei Supernatant of liver; 
nuclei 
- pituitary 
membranes 
+ pituitary 
membranes 
nuclei prepared with 
pituitary membranes 
- 
+ 
4157 f 381 99 + 155 680 + 174 2724 + 401 
3379 + 434 16 + 182 150+ 56 2251 t 312 
Nuclei were prepared from Long Evans male rat liver and pituitary as described in the text 
Table 3 
Nuclear and membrane binding of LH-RH agonist during the rat estrous cycle 
Kd (nM -+ SEM) 
Membranes Nuclei 
Q (fmol/pituitary) 
Membranes Nuclei 
Diestrus I 0.44 * 0.10 0.29 i 0.07 38.3 t 2.8 19.0 f 4.0 
Diestrus II 0.45 f 0.14 0.23 -t 0.04 61.5 f 5.1 32.7 IT 4.3 
Proestrus 0.35 f 0.03 0.25 -t 0.08 81.7 f 7.7 49.1 & 7.6 
Estrus 0.30 + 0.06 0.26 + 0.03 35.2 + 5.8 16.8 it 2.6 
Adult female Wistar rats were housed under a 14: 10 h 1ight:dark cycle. The stage of the estrous cycie was determined 
from vaginal smears. Between 24 and 45 females for each stage were decapitated at 10 a.m. Nuclei were prepared from 
the 1000 x g pellet by two successive resuspensions in fresh TEBD buffer and centrifugation at 1000 x g foilowed by 
centrifugation through 1.2 M sucrose TEBD at 9000 x g for 45 min. Data were calculated from Scatchard analysis of 
binding of the D-Ala6-agonist 
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fully characterised nuclei prepared in this way by 
enzyme marker and electron microscopic studies it 
is possible that a small proportion of the nuclear 
binding might be due to contaminating subcellular 
particulate material. 
4. DISCUSSION 
This study has demonstrated the presence of 
high affinity, specific nuclear binding sites for LH- 
RH in the rat anterior pituitary which have proper- 
ties similar to those of LH-RH membrane recep- 
tors. Since this binding could have been due to an 
association of LH-RH receptors in plasma mem- 
branes or other subcellular material with the nuclei 
during preparation we have undertaken studies to 
investigate this. A number of points argue against 
the possibility of signific~t contamination of the 
nuclei with non-nuclear LH-RH binding material. 
The nuclei were prepared by methodology 
previously shown to produce a purified prepara- 
tion [9-11,18,19] and bound LH-RH with a 
substantial capacity. The purity of these nuclei was 
established by electron microscopic examinations. 
The specific binding of ‘251-LH-RH analogue to 
nuclei relative to 5 ’ -nucleotidase activity indicates 
that the binding is not due to contamination with 
plasma membrane receptors. In other studies we 
demonstrated that purified liver nuclei bind LH- 
RH poorly when prepared with pituitary mem- 
branes (16% relative to pituitary nuclei) and that 
the majority of the membrane binding remained 
unassociated with the liver nuclei. When liver 
nuclei were prepared in the presence of pituitary 
membranes with 0.~1~0 Triton X-100 this binding 
was abolished while pituitary nuclear binding was 
still substantial. The site of LH-RH binding to the 
nucleus may be the chromatin or nuclear mem- 
branes. However, cytoskeletal filaments have not 
been excluded as possible LH-RH binding sites in 
our experiments ince they are an integral part of 
nuclei purified by both detergent and mechanical 
lysis, and are not easily revealed by electron 
microscopy [25]. Using conditions which remove 
all membranous material (2% Triton X-100) both 
nuclear and membrane binding of LH-RH were 
completely lost (not shown). 
The degree of LH-RH binding by purified nuclei 
represented 33.1 f 3.6% of the total binding of the 
pituitary which is somewhat higher than the 
relative binding of insulin (lO@?o) to isolated nuclei 
[9j. However, the binding of TRH to purified 
pituitary nuclei (15-205’0 of total cellular binding) 
[16] is similar to that of LH-RH. 
During the rat estrous cycle binding of LH-RH 
to pituitary membranes increased on the morning 
of proestrus [26] and the nuclear preparations ex- 
hibited a similar pattern. The findings do not ex- 
clude the possibility, however, that nuclear LH- 
RH binding might be different from that of mem- 
brane receptors during the afternoon of proestrus 
when membrane binding declines just prior to the 
preovulatory gonadotropin surge [27]. 
The role of LH-RH internalisation is unknown 
but the decrease in receptor number accompanying 
stimulation with high concentrations of LH-RH 
may be explained by internaiisation, separately, or 
in conjunction with, sequestration and degrada- 
tion by Iysosomes 121, Internalisation of LH-RH 
could also be related to binding to, and regulation 
of, subcellular organelles such as the nucleus, 
cytoskeletal filaments and secretory granules. LH- 
RH binding to nuclei might be responsible for the 
late events in LH-RH action, mediated via increas- 
ed protein synthesis as suggested for insulin [9J. 
Since the late phase of LH-RH-stimulated gonado- 
trophin release is impaired by inhibitors of protein 
synthesis [4,6] it is possible that LH-RH associa- 
tion with nuclei might serve a role in stimulating de 
novo synthesis of these hormones. Another late 
event in LH-RH action which may be dependent 
on LH-RH binding to nuclei is the stimulation of 
an increase in LH-RH membrane receptors on the 
pituitary gonadotroph [S]. 
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